GILD Stock Recent News
GILD LATEST HEADLINES
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close.
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead's commitment to helping address the evolving needs of a diverse range of people and com.
Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Gilead's lenacapavir may become a blockbuster HIV prophylactic. Biktarvy maintains a dominant market share in the HIV treatment space, contributing significantly to Gilead's revenue growth. Gilead's oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth.
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.